• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In-vitro susceptibility of oral streptococci to pristinamycin.

作者信息

Maskell J P, Williams J D

出版信息

J Antimicrob Chemother. 1987 May;19(5):585-90. doi: 10.1093/jac/19.5.585.

DOI:10.1093/jac/19.5.585
PMID:3112093
Abstract

The inhibitory activity of pristinamycin against oral streptococci was compared with that of amoxycillin, erythromycin and vancomycin. Minimum inhibitory concentrations (MICs) of pristinamycin ranged from 0.03-1 mg/l (mode 0.25 mg/l), similar to those for amoxycillin. Erythromycin had a mode MIC of 0.06 mg/l and vancomycin, the least active, 1 mg/l. However, in killing curve experiments to compare the bactericidal activities of pristinamycin and erythromycin against several strains of oral streptococci, pristinamycin was substantially more active, consistently producing a rapid decrease in viable count during the first few hours of incubation. Pristinamycin may prove to be of value for the prophylaxis of post-dental extraction bacteraemia.

摘要

相似文献

1
In-vitro susceptibility of oral streptococci to pristinamycin.
J Antimicrob Chemother. 1987 May;19(5):585-90. doi: 10.1093/jac/19.5.585.
2
Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin.红霉素、万古霉素和利奈唑胺的体外活性比较
Infection. 1988;16(6):365-70. doi: 10.1007/BF01644551.
3
Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organisms.阿奇霉素、大环内酯类药物(红霉素、克拉霉素和螺旋霉素)及链阳菌素RP 59500对口腔微生物的体外活性比较
J Antimicrob Chemother. 1992 Jul;30(1):27-37. doi: 10.1093/jac/30.1.27.
4
Antibiotic-resistant oral streptococci in dental patients susceptible to infective endocarditis.易患感染性心内膜炎的牙科患者中的耐抗生素口腔链球菌。
J Med Microbiol. 1991 Jan;34(1):33-7. doi: 10.1099/00222615-34-1-33.
5
Comparison of the in vitro activity of pristinamycin and quinupristin/dalfopristin against Streptococcus pneumoniae.普那霉素与奎奴普丁/达福普汀对肺炎链球菌的体外活性比较。
Pathol Biol (Paris). 2000 Jun;48(5):463-6.
6
[In vitro activity of pristinamycin against Streptococcus pneumoniae].
Pathol Biol (Paris). 2001 Sep;49(7):583-6. doi: 10.1016/s0369-8114(01)00202-4.
7
[Inhibitory and fatal activity of amoxicillin, erythromycin and josamycin against Streptococci].
G Batteriol Virol Immunol. 1981 Jul-Dec;74(7-12):283-96.
8
The in-vitro activity of pristinamycin against Haemophilus influenzae and Neisseria meningitidis.普那霉素对流感嗜血杆菌和脑膜炎奈瑟菌的体外活性。
J Antimicrob Chemother. 1985 Jul;16 Suppl A:221-3. doi: 10.1093/jac/16.suppl_a.221.
9
Resistance in oral streptococci after repeated two-dose amoxycillin prophylaxis.重复两剂阿莫西林预防后口腔链球菌的耐药性。
J Antimicrob Chemother. 1983 Aug;12(2):141-6. doi: 10.1093/jac/12.2.141.
10
In-vitro activity of pristinamycin and its components against gram-negative anaerobic bacilli and Gardnerella vaginalis.
J Antimicrob Chemother. 1989 Jun;23(6):825-30. doi: 10.1093/jac/23.6.825.

引用本文的文献

1
Delayed host mortality and immune response upon infection with persister cells.迟发性宿主死亡率和对持久性细胞感染的免疫反应。
Infect Immun. 2023 Oct 17;91(10):e0024623. doi: 10.1128/iai.00246-23. Epub 2023 Sep 21.
2
In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases.施复捷及相关药物对从败血症和心内膜炎病例中分离出的口腔链球菌的体外活性。
J Sci Res Med Sci. 2000 Jan;2(1):25-31.
3
Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin.红霉素、万古霉素和利奈唑胺的体外活性比较
Infection. 1988;16(6):365-70. doi: 10.1007/BF01644551.
4
In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.半合成注射用普那霉素RP 59500对葡萄球菌、链球菌和肠球菌的体外活性
Antimicrob Agents Chemother. 1991 Mar;35(3):553-9. doi: 10.1128/AAC.35.3.553.